Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 3/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4885842 | 0.88 | CHRM3 (0.57) | ADRA1DADRA1AADRA1BCHRM3CYP2J2 | |
| SCHEMBL4885835 | 0.80 | ADRA1D (0.48) | ADRA1DADRA1AADRA1BTSHRFAAH | |
| SCHEMBL11698547 | 0.76 | DPP7 (0.67) | ADRA1DADRA1AADRA1B | |
| SCHEMBL20689718 | 0.76 | ADRA1D (0.65) | ADRA1DADRA1AADRA1B | |
| SCHEMBL5774489 | 0.76 | TSHR (0.57) | ADRA1DADRA1AADRA1BTSHRFAAH | |
| SCHEMBL4886415 | 0.76 | CHRM3 (0.53) | ADRA1DADRA1AADRA1BCHRM3CYP2J2 | |
| SCHEMBL8983764 | 0.76 | CHRM3 (0.50) | ADRA1DADRA1AADRA1BCHRM3CYP2J2 | |
| SCHEMBL5277053 | 0.76 | ADRA1D (0.55) | ADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL11261146 | 0.75 | DPP7 (0.65) | ADRA1DADRA1AADRA1BKMT2A | |
| SCHEMBL14003889 | 0.75 | SIGMAR1 (0.60) | ADRA1DADRA1AADRA1BTSHRCHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280883-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-11-13 | — | — | US | claimed |
| US-20080280883-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-11-13 | — | — | US | disclosed |
| EP-1794161-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032994-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280883-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | ADRA1D 82/4885ADRA1A 70/4885ADRA1B 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.